print this page

Clinical Trials: Heart


A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease. FOURIER: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk. (IRB# BH-12-254)

(Heart, Vascular)
  • Principal Investor
    Gregory Giugliano, MD
  • Summary

    This study is for patients aged 40-80 who have had a heart attack or stroke with the past 5 years and

    Have one of the following risk factors:  type 2 diabetes, age 65-80, heart attack or stroke within past 6 months, 2 or more heart attacks or strokes, or history or symptomatic peripheral arterial disease or amputation in addition to a heart attack or stroke. 

    Or

    Have two or more of the following risk factors: history of non-heart attack related coronary revascularization, residual coronary artery disease, HDL-C < 40 mg/dL for men and < 50 mg/dL for women, hsCRP > 2.0 mg/L, final LDL-C > 130 mg/dL or non-HDL-C > 160 mg/dL, metabolic syndrome.

  • Study Site Location
    Baystate Heart and Vascular Research, 3300 Main St. Suite 1D, Springfield, MA
  • Contact
    Annette Scarnici, RN
    413.794.9076
    Email

Validity of Dyspnea Severity Measure in Acute Heart Failure: Pilot Study (IRB# 293448-23)

(Heart)
  • Principal Investor
    Howard Smithline, MD
  • Summary

    The purpose of this research study is, to see if we can accurately measure the severity of your breathlessness. 

  • More Information

    Eligibility:

    You must be at least 18 years old, admitted to the hospital with congestive heart failure and have shortness of breath.

  • Study Site Location
    Emergency Room Baystate Medical Center
  • Contact
    Kye Poronsky
    413.794.4421
    Email